Trial Profile
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms Neo Trio
- 13 Sep 2022 Results of histopathological analysis assessing the optimal combination of dabrafenib plus trametinib and pembrolizumab, presented at the 47th European Society for Medical Oncology Congress.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Status changed from recruiting to active, no longer recruiting.